https://www.********/investing/2017/10/22/can-teva-pharmaceuticals-dividend-even-survive.aspx
"It's hard to know where to begin with the negatives for Teva. Numerically, the biggest issue is the company's debt of $35.1 billion. Because of this huge debt load, Teva paid interest expenses of $436 million in the first half of 2017. Servicing its debt could legitimately be viewed as the primary threat to Teva's continuation of dividend payments."
https://www.********/investing/2017/10/22/can-teva-pharmaceutical...
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |